StockNews.AI
BLUE
StockNews.AI
14 days

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

1. Ayrmid Ltd. failed to submit a binding proposal to acquire bluebird bio. 2. bluebird bio reaffirms support for its transaction with Carlyle and SK Capital.

2 mins saved
Full Article

FAQ

Why Bullish?

The lack of a competitive proposal from Ayrmid keeps Carlyle and SK as preferred investors, maintaining stability. Historically, similar situations led to price increases when companies preferred stable acquisition negotiations.

How important is it?

The failure of Ayrmid to proceed with the acquisition and bluebird’s endorsement of Carlyle indicates a secure future. This development significantly affects investor sentiment and highlights market stability.

Why Short Term?

Immediate market reactions are likely as bluebird maintains support for Carlyle and SK Capital. Investors may react in the short term, anticipating a solidified deal.

Related Companies

CGSKT
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. (“Ayrmid”) has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the “Board”) reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and.

Related News